stenoparib (2X-121) / Eisai, Allarity Therap, Oncoheroes  >>  Phase 1
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
stenoparib (2X-121) / Allarity Therap, Oncoheroes
NCT05571969: Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

Recruiting
1
40
US
2X-121 and dovitinib
Allarity Therapeutics, Amarex Clinical Research
Advanced Solid Tumors
10/24
12/24

Download Options